Loading
Small-cell lung cancer is at least four diseases under the microscope's uniform appearance. Treat each by its transcription-factor subtype.
Small-cell lung cancer looks uniform under the microscope, but the Rudin and Gay classification splits it into transcription-factor subtypes: ASCL1-driven SCLC-A, which is DLL3-high and BCL-2 dependent, NEUROD1-driven SCLC-N, POU2F3-driven SCLC-P and the inflamed SCLC-I. The idea is to assign subtype prospectively by RNA or immunohistochemistry and treat each accordingly: tarlatamab for SCLC-A, immunotherapy for SCLC-I, Aurora kinase inhibitors for SCLC-N and PARP or ATR inhibitors for SCLC-P. The rationale is that these dependencies are reproducible in cell lines and xenografts, and a retrospective IMpower133 analysis suggested SCLC-I gained most from atezolizumab. The proposed test is a subtype-stratified umbrella trial in relapsed patients, and the evidence so far is preclinical.
One of the most cited trial reports Europe PMC returns for Tarlatamab in Small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Patients with small-cell lung cancer that has relapsed after chemotherapy now have a drug that works far better than topotecan or lurbinectedin, and it is the first T-cell engager approved for a solid tumour. Treatment requires inpatient monitoring for the first doses because of cytokine release syndrome, which most centres now manage on a short-stay basis. It does not yet apply to first-line treatment, where trials are ongoing.
The organising framework for every small-cell lung cancer trial designed since. It is also why the slow progress in the disease is now attributed to treating four diseases as one rather than to the biology being intractable.
One of the most cited trial reports Europe PMC returns for DLL3 in Small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy, DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer, DLL3, Tarlatamab.
Shares Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, DLL3, Tarlatamab, Limited-stage small-cell lung cancer.
Shares DLL3, Tarlatamab, Limited-stage small-cell lung cancer, PARP.
Shares Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, DLL3, Tarlatamab, Extensive-stage small-cell lung cancer.
Shares DLL3, Tarlatamab, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study, Run small-cell lung cancer as one platform with shared controls and subtype stratification, Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data, DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer.
Shares DLL3, Tarlatamab, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
Shares DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer, Tarlatamab, Extensive-stage small-cell lung cancer, Small-cell lung cancer.